drugset / Trial / NCT05016895

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

NCT05016895

NaSingle-groupOpen-labelHealth-services research

Summary

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.

Timeline

Start
2021-08-27
Primary completion
2024-06-30
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 20 mg/kg

Indications

No indication recorded.